2022-502022-41-00已完成1 期
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Moderna Inc.
- 入组人数
- 248
- 试验地点
- 15
- 主要终点
- Solicited local and systemic ARs through 7 days after each injection.
研究概览
简要总结
To evaluate the safety and reactogenicity of study injections
研究设计
- 分配方式
- Randomized
- 主要目的
- Part D
- 盲法
- Double (Subject, Investigator, Carer, Monitor)
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •The participant is male or female, 8 months to <24 months (Part A) or, 5 months to <8 months (Part B), 8 months to <12 months (Part C), or 5 months to <24 months (Part D) of age at the time of randomization (Day 1/Baseline visit), who is in good general health, in the opinion of the Investigator, based on review of medical history and screening physical examination. Common benign infant conditions (eg, mild to moderate GERD or atopic dermatitis not interfering with injection-site assessment) are allowed.
- •In the Investigator’s opinion, the parent(s)/LAR(s) understand and are willing and physically able to comply with protocol-mandated follow up, including all procedures, and provide written informed consent.
- •The participant is growing normally for age in the opinion of the site clinician in the months prior to enrollment.
- •The participant was born at full-term (≥37 weeks gestation) with a minimum birth weight of 2.5 kg.
- •Participant’s parent(s)/LAR(s) must have access to a consistent means of contact either by telephone contact or email/computer.
- •Part C Cohort 7 and Part D Cohorts 11 and 12: participant must have received nirsevimab ≥6 months prior to Day 1 Visit.
- •Part C Cohort 8: participant was eligible at any time since birth, according to national guidelines, to receive nirsevimab prior to Day 1 Visit but did not do so.
排除标准
- •Has a known history of symptomatic RSV (Part A: within 3 months; Part B, Part C, and Part D: since birth) or hMPV infection (Part A: within 3 months; Part B: since birth) prior to administration of the first dose of IP or has a known close contact with anyone with laboratory-confirmed RSV (Parts A, B, C, and D) or hMPV infection (Parts A or B) within 14 days prior to administration of the first dose of IP.
- •Is an immediate family member, or household contact, of an employee of the study site or the Sponsor or someone otherwise directly involved with the conduct of the study. As applicable, family members/household contacts of employees of the larger institution or affiliated private practice not part of the study site may be enrolled if the Investigator does not have any influence over their employment status.
- •A child who has been placed under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body acting in accordance with powers conferred on them by laws and regulation (eg, foster care). This does not include a child who is adopted or has an appointed legal guardian.
- •Is acutely ill or febrile 24 hours prior to or at the Screening Visit. Fever is defined as a body temperature ≥38.0°C/ ≥100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Participants who are afebrile with minor illnesses can be enrolled at the discretion of the Investigator.
- •Has previously been administered an investigational or approved vaccine for prevention of RSV (Parts A, B, C, and D) or hMPV (Parts A and B) infection or if the participant’s mother received an investigational or approved vaccine for the prevention of RSV (Part A, B, C, and D) or hMPV (Parts A and B) infection during pregnancy. a. Part D (Cohorts 9 and 10): Use of approved vaccine during pregnancy for the prevention of RSV infection is allowed.
- •Has received investigational or approved agents for prophylaxis against RSV or hMPV (eg, monoclonal antibodies), or is intending to receive these during the course of the study. a. Part C (Cohort 7 only) and Part D (Cohorts 11 and 12 only): Use of nirsevimab ≥6 months before Day 1 Visit is allowed.
- •Has a known hypersensitivity to a component of the vaccine or its excipients. Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA vaccine or any of its components (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate).
- •Has a medical condition that, according to the Investigator’s judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.
- •Has a history of diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: a. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination. b. Serious chronic illness c. Major congenital defects d. History of any neurological disorders or seizures e. History of or current autoimmune disease f. History of recurrent wheezing (wheezing should have been verified on auscultation by a doctor) g. History of chronic cough (8 weeks or more duration) h. Previous hospitalization for respiratory illnesses i. History of thrombocytopenia j. History of anemia k. Neurological complications following any prior vaccination l. Born to a mother known or suspected to be HIV positive or Hepatitis C positive (no laboratory testing required) m. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required) n. Chronic hepatitis or suspected active hepatitis o. A bleeding disorder that is considered a contraindication to IM injection or phlebotomy p. Dermatologic conditions that could affect local solicited AR assessments q. Family history of congenital or hereditary immunodeficiency
- •Has received the following: a. Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days prior through 7 days after IP administration. b. Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 mg/kg/day or ≥10 mg/day prednisone equivalent, if participant weighs >10 kg). Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed. c. Intravenous or subcutaneous blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment.
- •Has participated in an interventional clinical study within 28 days prior to the Screening Visit or plans to do so while participating in this study.
结局指标
主要结局
Solicited local and systemic ARs through 7 days after each injection.
Solicited local and systemic ARs through 7 days after each injection.
Unsolicited AEs through 28 days after each injection.
Unsolicited AEs through 28 days after each injection.
MAAEs from Day 1 to EoS.
MAAEs from Day 1 to EoS.
AESIs from Day 1 to EoS.
AESIs from Day 1 to EoS.
SAEs from Day 1 to EoS.
SAEs from Day 1 to EoS.
AEs leading to discontinuation from Day 1 to EoS.
AEs leading to discontinuation from Day 1 to EoS.
次要结局
- GMT of serum RSV and hMPV neutralizing antibody across prespecified study timepoints. In Part C and Part D, GMT and GMC will be done only for RSV.
- Number and percentage of participants with RTI, LRTI, severe LRTI, very severe LRTI, and hospitalizations associated with RSV or hMPV from Day 1 through EoS.
- GMC of serum RSV F and hMPV F– binding antibody across prespecified study timepoints. In Part C and Part D, GMT and GMC will be done only for RSV.
- GMFR of postbaseline/baseline neutralizing antibody titers and binding antibody concentrations across prespecified study timepoints.
- Frequency, magnitude, and/or phenotype of vaccine-specific T-cell responses measured by flow cytometry or other methods. Cellular immunogenicity will not be done in Part B and Part D.
研究者
Matthew Snape
Scientific
Moderna Therapeutics Inc.
研究点 (15)
Loading locations...
相似试验
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold UrticariaNCT07266402Celldex Therapeutics240
已完成
2 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease2024-512756-38-00Boehringer Ingelheim International GmbH27
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
已完成
1 期
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32